ACTRN12613000727741尚未招募未知
Dexamphetamine to treat obesity complicated by diabetes or obstructive sleep apnoea
epean Hospital0 个研究点目标入组 24 人开始时间: 2013年7月2日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •BMI greater than 30
- •and either obstructive sleep apnoea on PAP
- •or Type 2 diabetes mellitus
排除标准
- •History of addiction to illicit drugs, uncontrolled hypertension greater than 140/90, symptomatic ischaemic heart disease, significant kidney or liver disease, uncontrolled epilepsy, weight change of more than 3kg the past 3 months, breastfeeding, pregnant or planning pregnancy, history of bariatric surgery, current depression or other psychiatric illness, current treatment with psychotropic medication, systemic glucocorticoids or medication for weight loss (eg orlistat), family history of sudden death from cardiac causes, hypersensitivity to dexamphetamine or any components of the tablet.
研究者
相似试验
进行中（未招募）
1 期
Dapiglutide for the treatment of obesity (DREAM): a randomised, double-blind, placebo-controlled, investigator-initiated trialObesityCTIS2022-501649-54-01Gentofte Hospital54
进行中（未招募）
1 期
Treatment of antipsychotic associated obesity with an antidiabetic agent: the TAO studyObesityEUCTR2012-005404-17-DKCenter for Neuropsychiatric Schizophrenia Research45
已完成
4 期
Effects of Dexmedetomidine infusion on heamodynamic responses in patients undergoing microlaryngoscopyCTRI/2016/01/006551okmanya Tilak Municipal Medical College and General Hospital60
已完成
不适用
Pharmacokinetics of new dexamphetamine sustained release tablets and the clinical validation of measuring dexamphetamine in dried blood spotsMiddelenafhankelijkheidAddictive behaviourAddictionNL-OMON44699Di-AcetylM B.V.16
进行中（未招募）
1 期
Blood levels of dexamphetamine sustained release tablets and the review of the usefulness of measuring dexamphetamine in dried blood spotso condition is investigated. The primary aim is to investigate the pharmacokinetics of the new formulationEUCTR2015-002403-29-NLDi-AcetylM B.V.